Tissue factor pathway inhibitor protects the ischemic spinal cord

Journal of Surgical Research

Volumn 63, Issue 1, 1996, Pages 174-178

  Koudsi, Basem ^a   Chatman, David M ^b   Ballinger, Beth A ^b   Ferguson, Edward W ^a   Kraemer, Bruce A ^a   Miller, Gary A ^a   Wun, Tze Chein ^c   Farr, Gist ^b   Money, Samuel R ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c MONSANTO COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; HEPARIN; THROMBOPLASTIN; THROMBOPLASTIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; SPINAL CORD BLOOD FLOW; SPINAL CORD ISCHEMIA; TREATMENT OUTCOME;

EID: 0029948524     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0243     Document Type: Conference Paper

References (35)

1. Crawford, E. S., Crawford, J. L., and Safi, H. J., et al. Thoracoabdominal aortic aneurysms: Preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J. Vasc. Surg. 3: 389-404, 1986.
2. Hollier, L. H., and Moore, W. M. Avoidance of renal and neurologic complications following thoracoabdominal aortic aneurysm repair. Acta Chir. Scand. 555(Suppl): 129-135, 1990.
3. Svensson, L. G., Crawford, E. S., and Hess, K. R., et al. Experience with 1509 patients undergoing thoracoabdominal operations. J. Vasc. Surg. 17: 357-368, 1993.
4. Verdant, A. Descending thoracic aortic aneurysms: Surgical treatment with the Gott shunt. Can. J. Surg. 35: 493-496, 1992.
5. Kirschner, R. E., and Fantini, G. A. Role of iron and oxygen-derived free radicals in ischemia-reperfusion injury. J. Am. Coll. Surg. 179: 103-117, 1994.
6. Archer, C. W., Wynn, M. M., and Archibald, J. Naloxone and spinal fluid drainage as adjuncts in the surgical treatment of thoracoabdominal and thoracic aneurysms. Surgery 108: 744-762, 1990.
7. Livesay, J. J., Cooley, D. A., and Ventimiglia, T. A., et al. Surgical experience in descending thoracic aneurysmectomy with and without adjuncts to avoid ischemia. Ann. Thorac. Surg. 39: 37-46, 1985.
8. Crawford, E. S., Walker, H. S., and Saleh, S. A., et al. Graft replacement of aneurysm in the descending thoracic aorta: Results without bypass or shunting. Surgery 89: 73-85, 1981.
9. Jex, R. K., Schaff, H. V., and Piehler, J. M., et al. Early and late results following repair of dissection of the descending thoracic aorta. J. Vasc. Surg. 3: 226-237, 1986.
10. Hollier, L. H., Symmonds, J. B., and Pairolero, P. C., et al. Thoracoabdominal aortic aneurysm repair: analysis of postoperative morbidity. Arch. Surg. 123: 871-875, 1988.
11. McCullough, J. L., Hollier, L. H., and Nugent, M. Paraplegia after thoracic aortic occlusion; influence of cerebrospinal fluid drainage. J. Vasc. Surg. 7: 153-160, 1988.
12. Compeau, C. G., Ma, J., and DeCampos, K. N., et al. In situ ischemia and hypoxia enhance alveolar macrophage tissue factor expression. Am. J. Respir. Cell Med. Biol. 11(4): 446-455, 1994.
13. Van 'tVeer, C., Hackeng, T. M., and Delahaye, C., et al. Activated factor Y and thrombin formation triggered by tissue factor or endothelial cell matrix in a flow model: Effect of the tissue factor pathway inhibitor. Blood 84(4): 1132-1142, 1994.
14. Khouri, R. K., Koudsi, B., and Kaiding, F., et al. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann. Plast. Surg. 30(5): 398-402, 1993. (Discussion 402-404).
15. Kraemer, B. A., Yu, C., and Ornberg, R. L., et al. The effect of tissue factor pathway inhibitor (TFPI) on tissue ischemia and reperfusion in a rabbit ear model. Surg. Forum. 51: 738-740, 1995.
16. Ferguson, E. W., Jr., Koudsi, B., and Miller, G. A., et al. Tissue factor pathway inhibitor enhancement of skeletal muscle viability following ischemia. Surg. Forum 51: 728-730, 1995.
17. Koudsi, B., Yu, C. D., Ferguson, E. W., Jr., Miller, G. A., Kurt, D., Merkel, Wun, T-C., and Kraemer, B. A.: Prevention of spinal cord injury following transient aortic clamping using tissue factor pathway inhibitor (TFPI). Surgery, in press.
18. Thomas, W. S., Mori, E., and Copeland, B. R., et al. Tissue factor contributes to microvascular defects after focal cerebral ischemia. Stroke, 24(6): 847-853, 1993.
19. Mori, E., del Zoppo, C. J., and Chambers, J. D., et al. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 23(5): 712-718, 1992.
20. Naslund, T. C., Hollier, L. H., and Money, S. R., et al. Protecting the ischemic spinal cord during aortic clamping. Ann. Surg. 215: 409-416, 1992.
21. Granke, K., Hollier, L. H., and Moore, W. M., et al. Paraplegia following thoracic aorta cross-clamping in the canine model: Effect of interventional therapy. J. Vasc. Surg. 13: 615-621, 1991.
22. Wisselink, W., Money, S. R., and Crockett, D. E., et al. Ischemia-reperfusion injury of the spinal cord: Protective effect of the hydroxyl radical scavenger dimethylthiourea. J. Vasc. Surg. 20: 444-450, 1994.
23. Hollier, L. H. Protecting the brain and spinal cord. J. Vasc. Surg. 5: 524-528, 1987.
24. Jacobs, T. P., Shohami, E., Baze, W., et al. Deteriorating stroke model: Histopathology, edema, and eicosanoid changes following spinal cord ischemia in rabbits. Stroke 18: 741-750, 1987.
25. Schmidly, J. W. Free radicals in central nervous system ischemia. Stroke 21: 1086-1090, 1990.
26. Chan, P. H. The role of oxygen radicals in brain injury and edema. In C. K. Chow (Ed.), Cellular Antioxidant Defense Mechanisms, Volume III. Boca Raton, Florida: CRC Press, Inc., 1988. Pp. 89-109.
27. Rao, L. V., and Ruf, W. Tissue factor residues LYS165 and LYS166 are essential for rapid formation of the quaternary complex of tissue factor VIIa with Xa tissue factor pathway inhibitor. Biochemistry, 34(34): 10867-10871, 1995.
28. Edwards, L., and Rickles, R. F. The role of leukocytes in the activation of blood coagulation. Sem. in Hematol. 29(3): 202-212, 1992.
29. Lindahl, A. K., Sandset, P. M., and Abildgaard, V. The present status of tissue factor pathway inhibitor. Blood Coagul. Fibrinol. 3(4): 439-449, 1992.
30. Palmier, M. O., Hall, L. J., Reisch, M., and Baldwin, M. K., et al. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb. Haemostasis 68(1): 33-36, 1992.
31. Weiss, S. J. Oxygen, ischemia and inflammation. Acta Physiol. Scand. 548(Suppl.): 9-37, 1986.
32. Hoppensteadt, D. A., Walenga, J. M., and Fasquella, A., et al. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb. Res. 77(2): 175-185, 1995.
33. Hoppensteadt, D. A., Jeske, W., Fareed, J., and Bermes, E. W., Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coagul. Fibrinol. 6(Suppl)1: 557-564, 1995.
34. Harenberg, J., Malsch, R., and Heene, D. L. Tissue factor pathway inhibitor: Proposed heparin recognition region. Blood Coagul. Fibrinol. 6(Suppl)1: 550-556, 1995.
35. Kaiser, B., Hoppensteadt, D. A., Jeske, W., et al. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb. Res. 75(6): 609-616, 1994.